Skip to main content
Top
Published in: Pathology & Oncology Research 3/2019

01-07-2019 | Original Article

Predictive Factors of Lateral Lymph Node Metastasis in Papillary Thyroid Microcarcinoma

Authors: Wenjing Zhao, Shaobo Chen, Xianming Hou, Quan Liao, Ge Chen, Yupei Zhao

Published in: Pathology & Oncology Research | Issue 3/2019

Login to get access

Abstract

This study was designed to determine the incidence and predictive factors for lateral lymph node metastasis (LNM) in patients with papillary thyroid microcarcinoma (PTMC). From January 2014 to July 2015, a retrospective review was conducted of 215 patients with PTMC who underwent total thyroidectomy and central lymph node dissection (LND) with lateral LND. Correlations of lateral LNM with clinicopathological features were examined using univariate analyses. Risk factors for lateral LNM were identified by multivariate analysis. Lateral LNM was observed in 163(75.8%) cases of 215 patients and often involved in level III (82.2%) and level IV (65.6%), with most found in two-levels (41.1%) and single-level (33.7%) models. Multivariate analyses showed that central LNM (odds ratio [OR]: 8.28, 95% confidence interval [CI]: 3.43–19.98, p < 0.001) and upper portion location (OR: 2.87 [CI: 1.34–6.09]; p = 0.007) were independent predictive factors for lateral LNM. The incidence of skip metastasis-Lateral LNM with central Lymph nodes negative-was 8.6% (14/163). Age ≥ 45 years old (OR: 4.37 [CI: 1.14–16.66]; p = 0.031) and upper portion location (OR: 4.34 [CI: 1.27–14.78]; p = 0.019) were independent risk factors for skip metastasis by multivariate analyses. Taken together, patients with PTMC with central LNM and tumor in the upper pole were more likely to present with lateral LNM. Even if there was no central LNM, patients with an age ≥ 45 years old and tumors in the upper portion of the thyroid should be evaluated carefully for possible lateral LNM.
Literature
1.
go back to reference Yu XM, Wan Y, Sippel RS, Chen H (2011) Should all papillary thyroid microcarcinomas be aggressively treated? An analysis of 18,445 cases. Ann Surg 254:653–660CrossRefPubMed Yu XM, Wan Y, Sippel RS, Chen H (2011) Should all papillary thyroid microcarcinomas be aggressively treated? An analysis of 18,445 cases. Ann Surg 254:653–660CrossRefPubMed
2.
go back to reference Chow SM, Law SC, Chan JK, Au SK, Yau S, Lau WH (2003) Papillary microcarcinoma of the thyroid: prognostic significance of lymph node metastasis and multifocality. Cancer 98:31–40CrossRefPubMed Chow SM, Law SC, Chan JK, Au SK, Yau S, Lau WH (2003) Papillary microcarcinoma of the thyroid: prognostic significance of lymph node metastasis and multifocality. Cancer 98:31–40CrossRefPubMed
3.
go back to reference Pisanu A, Reccia I, Nardello O, Uccheddu A (2009) Risk factors for nodal metastasis and recurrence among patients with papillary thyroid microcarcinoma: differences in clinical relevance between nonincidental and incidental tumors. World J Surg 33:460–468CrossRefPubMed Pisanu A, Reccia I, Nardello O, Uccheddu A (2009) Risk factors for nodal metastasis and recurrence among patients with papillary thyroid microcarcinoma: differences in clinical relevance between nonincidental and incidental tumors. World J Surg 33:460–468CrossRefPubMed
4.
go back to reference Hay ID, Hutchinson ME, Gonzalez Losada T (2008) Papillary thyroid microcarcinoma: a study of 900 cases observed in a 60-year period. Surgery 144:980–988CrossRefPubMed Hay ID, Hutchinson ME, Gonzalez Losada T (2008) Papillary thyroid microcarcinoma: a study of 900 cases observed in a 60-year period. Surgery 144:980–988CrossRefPubMed
5.
go back to reference Machens A, Hinze R, Thomusch O, Dralle H (2002) Pattern of nodal metastasis for primary and reoperative thyroid cancer. World J Surg 26:22–28CrossRefPubMed Machens A, Hinze R, Thomusch O, Dralle H (2002) Pattern of nodal metastasis for primary and reoperative thyroid cancer. World J Surg 26:22–28CrossRefPubMed
6.
go back to reference Shaha AR (1998) Management of the neck in thyroid cancer. Otolaryngol Clin N Am 31:823–831CrossRef Shaha AR (1998) Management of the neck in thyroid cancer. Otolaryngol Clin N Am 31:823–831CrossRef
7.
go back to reference Machens A, Holzhausen H, Dralle H (2004) Skip metastases in thyroid cancer leaping the. Central lymph node compartment. Arch Surg 139:43–45CrossRefPubMed Machens A, Holzhausen H, Dralle H (2004) Skip metastases in thyroid cancer leaping the. Central lymph node compartment. Arch Surg 139:43–45CrossRefPubMed
8.
go back to reference Lim YC, Koo BS (2012) Predictive factors of skip metastases to lateral neck compartment. Leaping central neck compartment in papillary thyroid carcinoma. Oral Oncol 48:262–265CrossRefPubMed Lim YC, Koo BS (2012) Predictive factors of skip metastases to lateral neck compartment. Leaping central neck compartment in papillary thyroid carcinoma. Oral Oncol 48:262–265CrossRefPubMed
9.
go back to reference Lee YS, Shin SC, Lim YS et al (2014) Tumor location–dependent skip lateral cervical lymph node metastasis in papillary thyroid cancer. Head Neck 36:887–891CrossRefPubMed Lee YS, Shin SC, Lim YS et al (2014) Tumor location–dependent skip lateral cervical lymph node metastasis in papillary thyroid cancer. Head Neck 36:887–891CrossRefPubMed
10.
go back to reference Wada N, Duh QY, Sugino K et al (2003) Lymph node metastasis from 259 papillary. Thyroid microcarcinomas: frequency, pattern of occurrence and recurrence, and optimal strategy for neck dissection. Ann Surg 237:399–407PubMedPubMedCentral Wada N, Duh QY, Sugino K et al (2003) Lymph node metastasis from 259 papillary. Thyroid microcarcinomas: frequency, pattern of occurrence and recurrence, and optimal strategy for neck dissection. Ann Surg 237:399–407PubMedPubMedCentral
11.
go back to reference Kim YS (2012) Patterns and predictive factors of lateral lymph node metastasis in papillary thyroid microcarcinoma. Otolaryngol Head Neck Surg 147:15–19CrossRefPubMed Kim YS (2012) Patterns and predictive factors of lateral lymph node metastasis in papillary thyroid microcarcinoma. Otolaryngol Head Neck Surg 147:15–19CrossRefPubMed
12.
go back to reference Chung YS, Kim JY, Bae JS et al (2009) Lateral lymph node metastasis in papillary thyroid carcinoma: results of therapeutic lymph node dissection. Thyroid 19:241–246CrossRefPubMed Chung YS, Kim JY, Bae JS et al (2009) Lateral lymph node metastasis in papillary thyroid carcinoma: results of therapeutic lymph node dissection. Thyroid 19:241–246CrossRefPubMed
14.
go back to reference Pelizzo MR, Boschin IM, Toniato A et al (2004) Natural history, diagnosis, treatment and outcome of papillary thyroid microcarcinoma (PTMC): a mono-institutional 12-year experience. Nucl Med Commun 25:547–552CrossRefPubMed Pelizzo MR, Boschin IM, Toniato A et al (2004) Natural history, diagnosis, treatment and outcome of papillary thyroid microcarcinoma (PTMC): a mono-institutional 12-year experience. Nucl Med Commun 25:547–552CrossRefPubMed
15.
go back to reference Roh JL, Kim JM, Park CI (2008) Lateral cervical lymph node metastases from papillary thyroid carcinoma: pattern of nodal metastases and optimal strategy for neck dissection. Ann Surg Oncol 15:1177–1182CrossRefPubMed Roh JL, Kim JM, Park CI (2008) Lateral cervical lymph node metastases from papillary thyroid carcinoma: pattern of nodal metastases and optimal strategy for neck dissection. Ann Surg Oncol 15:1177–1182CrossRefPubMed
16.
go back to reference Kwak JY, Kim EK, Kim MJ et al (2009) Papillary microcarcinoma of the thyroid: predicting factors of lateral neck node metastasis. Ann Surg Oncol 16:1348–1355CrossRefPubMed Kwak JY, Kim EK, Kim MJ et al (2009) Papillary microcarcinoma of the thyroid: predicting factors of lateral neck node metastasis. Ann Surg Oncol 16:1348–1355CrossRefPubMed
17.
go back to reference Lee KJ, Cho YJ, Kim SJ et al (2011) Analysis of the clinicopathologic features of papillary thyroid microcarcinoma based on 7-mm tumor size. World J Surg 35:318–323CrossRefPubMed Lee KJ, Cho YJ, Kim SJ et al (2011) Analysis of the clinicopathologic features of papillary thyroid microcarcinoma based on 7-mm tumor size. World J Surg 35:318–323CrossRefPubMed
18.
go back to reference Yang Y, Chen C, Chen Z et al (2014) Prediction of central compartment lymph node metastasis in papillary thyroid microcarcinoma. Clin Endocrinol 81:282–288CrossRef Yang Y, Chen C, Chen Z et al (2014) Prediction of central compartment lymph node metastasis in papillary thyroid microcarcinoma. Clin Endocrinol 81:282–288CrossRef
19.
go back to reference Zeng RC, Li Q, Lin KL et al (2012) Predicting the factors of lateral lymph node metastasis in papillary microcarcinoma of the thyroid in eastern China. Clin Transl Oncol 14:842–847CrossRefPubMed Zeng RC, Li Q, Lin KL et al (2012) Predicting the factors of lateral lymph node metastasis in papillary microcarcinoma of the thyroid in eastern China. Clin Transl Oncol 14:842–847CrossRefPubMed
20.
go back to reference Kwak JY, Kim EK, Youk JH et al (2008) Extrathyroid extension of well-differentiated papillary thyroid microcarcinoma on US. Thyroid 18:609–614CrossRefPubMed Kwak JY, Kim EK, Youk JH et al (2008) Extrathyroid extension of well-differentiated papillary thyroid microcarcinoma on US. Thyroid 18:609–614CrossRefPubMed
21.
go back to reference Lim YS, Lee JC, Lee YS et al (2011) Lateral cervical lymph node metastases from papillary thyroid carcinoma: predictive factors of nodal metastasis. Surgery 150:116–121CrossRefPubMed Lim YS, Lee JC, Lee YS et al (2011) Lateral cervical lymph node metastases from papillary thyroid carcinoma: predictive factors of nodal metastasis. Surgery 150:116–121CrossRefPubMed
22.
go back to reference Lin KL, Wang OC, Zhang XH, Dai XX, Hu XQ, Qu JM (2010) The BRAF mutation is predictive of aggressive Clinicopathological characteristics in papillary thyroid microcarcinoma. Ann Surg Oncol 17:3294–3300CrossRefPubMed Lin KL, Wang OC, Zhang XH, Dai XX, Hu XQ, Qu JM (2010) The BRAF mutation is predictive of aggressive Clinicopathological characteristics in papillary thyroid microcarcinoma. Ann Surg Oncol 17:3294–3300CrossRefPubMed
23.
go back to reference Ito Y, Tomoda C, Uruno T et al (2004) Papillary microcarcinoma of the thyroid: how should it be treated? World J Surg 28:1115–1121CrossRefPubMed Ito Y, Tomoda C, Uruno T et al (2004) Papillary microcarcinoma of the thyroid: how should it be treated? World J Surg 28:1115–1121CrossRefPubMed
24.
go back to reference Chung YS, Kim JY, Bae JS et al (2009) Lateral lymph node metastasis in papillary thyroid carcinoma: results of therapeutic lymph node dissection. Thyroid 19:241–245CrossRefPubMed Chung YS, Kim JY, Bae JS et al (2009) Lateral lymph node metastasis in papillary thyroid carcinoma: results of therapeutic lymph node dissection. Thyroid 19:241–245CrossRefPubMed
25.
go back to reference Verburg FA, Mader U, Tanase K et al (2013) Life expectancy is reduced in differentiated thyroid cancer patients≥45 years old with extensive local tumor invasion, lateral lymph node, or distant metastases at diagnosis and normal in all other DTC patients. J Clin Endocrinol Metab 98:172–180CrossRefPubMed Verburg FA, Mader U, Tanase K et al (2013) Life expectancy is reduced in differentiated thyroid cancer patients≥45 years old with extensive local tumor invasion, lateral lymph node, or distant metastases at diagnosis and normal in all other DTC patients. J Clin Endocrinol Metab 98:172–180CrossRefPubMed
Metadata
Title
Predictive Factors of Lateral Lymph Node Metastasis in Papillary Thyroid Microcarcinoma
Authors
Wenjing Zhao
Shaobo Chen
Xianming Hou
Quan Liao
Ge Chen
Yupei Zhao
Publication date
01-07-2019
Publisher
Springer Netherlands
Published in
Pathology & Oncology Research / Issue 3/2019
Print ISSN: 1219-4956
Electronic ISSN: 1532-2807
DOI
https://doi.org/10.1007/s12253-018-0511-8

Other articles of this Issue 3/2019

Pathology & Oncology Research 3/2019 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine